News articles about Cepheid (NASDAQ:CPHD) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cepheid earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the scientific and technical instruments company an impact score of 45.7220252974546 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

The company has a debt-to-equity ratio of 0.76, a current ratio of 4.30 and a quick ratio of 3.24.

WARNING: “Cepheid (CPHD) Receives News Sentiment Score of 0.18” was first reported by Marea Informative and is the sole property of of Marea Informative. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.mareainformativa.com/2018/03/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cepheid-cphd-share-price-updated-updated-updated.html.

Cepheid Company Profile

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Insider Buying and Selling by Quarter for Cepheid (NASDAQ:CPHD)

Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.